NCT04318600View on ClinicalTrials.gov

Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

March 1, 2017

Study Completion Date

January 1, 2019

Conditions
Lupus NephritisMesenchymal Stem Cells
Interventions
DRUG

human amniotic mesenchymal stem cell

human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).

All Listed Sponsors
collaborator

The First People's Hospital of Yunnan

OTHER

lead

Yan'an Affiliated Hospital of Kunming Medical University

OTHER

NCT04318600 - Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis | Biotech Hunter | Biotech Hunter